Olmesartán/Amlodipino/Hidroclorotiazida Krka (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine and hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Krka, are a combination antihypertensive presented as tablets for oral use. They treat high blood pressure in adult patients, helping to achieve target blood pressure levels and reduce cardiovascular risk.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under GMP conditions.

Olmesartan/amlodipine/hydrochlorothiazide is a combination antihypertensive used to manage elevated blood pressure and related cardiovascular conditions.

- Hypertension: lowers systolic and diastolic blood pressure to achieve guideline‑recommended targets. - Hypertension with diabetes: provides effective blood pressure control while minimizing metabolic impact. - Resistant hypertension: adds complementary mechanisms to improve control when monotherapy is insufficient.

The combination may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Increased urination: due to diuretic component.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte imbalance: low potassium or sodium levels. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips or airway requiring urgent care.

Before initiating therapy, several precautions should be considered to ensure safe use.

- Monitor blood pressure: check regularly to avoid excessive lowering. - Assess renal function: baseline and periodic creatinine measurements are recommended. - Check electrolytes: especially potassium and sodium levels during treatment. - Use with caution in hepatic impairment: dose adjustment may be required. - Contraindicated in pregnancy: avoid use during the second and third trimesters. - Store at room temperature: keep in the original container, protect from moisture and light.

Olmesartan/amlodipine/hydrochlorothiazide can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase risk of renal impairment. - Potassium‑sparing diuretics or supplements: may cause hyperkalaemia. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise amlodipine concentrations. - Beta‑blockers: additive blood‑pressure lowering effect may require monitoring.